NCT02455557: A trial that was reported late by Roswell Park Cancer Institute
This trial has reported, although it was 55 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02455557 |
|---|---|
| Title | A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 4, 2015 |
| Completion date | Oct. 23, 2019 |
| Required reporting date | Oct. 22, 2020, midnight |
| Actual reporting date | Dec. 17, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 55 |